Literature DB >> 22013219

Description of antiviral treatment among adults hospitalized with influenza before and during the 2009 pandemic: United States, 2005-2009.

Saumil Doshi1, Laurie Kamimoto, Lyn Finelli, Alejandro Perez, Arthur Reingold, Ken Gershman, Kimberly Yousey-Hindes, Kathryn Arnold, Patricia Ryan, Ruth Lynfield, Craig Morin, Joan Baumbach, Emily B Hancock, Nancy M Bennett, Shelley Zansky, Ann Thomas, William Schaffner, Alicia M Fry.   

Abstract

BACKGROUND: The 2009 influenza pandemic led to guidelines emphasizing antiviral treatment for all persons hospitalized with influenza, including pregnant women. We compared antiviral use among adults hospitalized with influenza before and during the pandemic.
METHODS: The Emerging Infections Program conducts active population-based surveillance for persons hospitalized with community-acquired, laboratory-confirmed influenza in 10 states. We analyzed data collected via medical record review of patients aged ≥18 years admitted during prepandemic (1 October 2005 through 14 April 2009) and pandemic (15 April 2009 through 31 December 2009) time frames.
RESULTS: Of 5943 adults hospitalized with influenza in prepandemic seasons, 3235 (54%) received antiviral treatment, compared with 4055 (82%) of 4966 during the pandemic. Forty-one (22%) of 187 pregnant women received antiviral treatment in prepandemic seasons, compared with 369 (86%) of 430 during the pandemic. Pregnancy was a negative predictor of antiviral treatment before the pandemic (adjusted odds ratio [aOR], 0.24; 95% confidence interval [CI], .16-.35) but was independently associated with treatment during the pandemic (aOR, 1.97; 95% CI, 1.32-2.96). Antiviral treatment among adults hospitalized >2 days after illness onset increased from 43% before the pandemic to 79% during the pandemic (P < .001).
CONCLUSIONS: Antiviral treatment of hospitalized adults increased during the pandemic, especially among pregnant women. This suggests that many clinicians followed published guidance to treat hospitalized adults with antiviral agents. However, compliance with antiviral recommendations could be improved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22013219     DOI: 10.1093/infdis/jir648

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

1.  Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model.

Authors:  Jacqueline M McBride; Jeremy J Lim; Tracy Burgess; Rong Deng; Michael A Derby; Mauricio Maia; Priscilla Horn; Omer Siddiqui; Daniel Sheinson; Haiyin Chen-Harris; Elizabeth M Newton; Dimitri Fillos; Denise Nazzal; Carrie M Rosenberger; Maikke B Ohlson; Rob Lambkin-Williams; Hosnieh Fathi; Jeffrey M Harris; Jorge A Tavel
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

2.  Oseltamivir Use Among Children and Adults Hospitalized With Community-Acquired Pneumonia.

Authors:  Ikwo K Oboho; Anna Bramley; Lyn Finelli; Alicia Fry; Krow Ampofo; Sandra R Arnold; Wesley H Self; Derek J Williams; D Mark Courtney; Yuwei Zhu; Evan J Anderson; Carlos G Grijalva; Jonathan A McCullers; Richard G Wunderink; Andrew T Pavia; Kathryn M Edwards; Seema Jain
Journal:  Open Forum Infect Dis       Date:  2016-12-27       Impact factor: 3.835

3.  Increased Antiviral Treatment Among Hospitalized Children and Adults With Laboratory-Confirmed Influenza, 2010-2015.

Authors:  Grace D Appiah; Sandra S Chaves; Pam D Kirley; Lisa Miller; James Meek; Evan Anderson; Oluwakemi Oni; Patricia Ryan; Seth Eckel; Ruth Lynfield; Marisa Bargsten; Shelley M Zansky; Nancy Bennett; Krista Lung; Christie McDonald-Hamm; Ann Thomas; Diane Brady; Mary L Lindegren; William Schaffner; Mary Hill; Shikha Garg; Alicia M Fry; Angela P Campbell
Journal:  Clin Infect Dis       Date:  2016-11-10       Impact factor: 9.079

Review 4.  Antivirals in the 2009 pandemic--lessons and implications for future strategies.

Authors:  Deeva Berera; Maria Zambon
Journal:  Influenza Other Respir Viruses       Date:  2013-11       Impact factor: 4.380

5.  Influenza antiviral treatment in spinal cord injury patients, 2007-2010.

Authors:  Charlesnika T Evans; Thea J Rogers; Barry Goldstein; Frances M Weaver; Sherri L LaVela
Journal:  J Spinal Cord Med       Date:  2014-06-24       Impact factor: 1.985

6.  Use of influenza antiviral agents by ambulatory care clinicians during the 2012-2013 influenza season.

Authors:  Fiona Havers; Swathi Thaker; Jessie R Clippard; Michael Jackson; Huong Q McLean; Manjusha Gaglani; Arnold S Monto; Richard K Zimmerman; Lisa Jackson; Josh G Petrie; Mary Patricia Nowalk; Krissy K Moehling; Brendan Flannery; Mark G Thompson; Alicia M Fry
Journal:  Clin Infect Dis       Date:  2014-07-16       Impact factor: 9.079

7.  Cost-effectiveness of seasonal inactivated influenza vaccination among pregnant women.

Authors:  Jing Xu; Fangjun Zhou; Carrie Reed; Sandra S Chaves; Mark Messonnier; Inkyu K Kim
Journal:  Vaccine       Date:  2016-05-06       Impact factor: 3.641

8.  Public health management of antiviral drugs during the 2009 H1N1 influenza pandemic: a survey of local health departments in California.

Authors:  Jennifer C Hunter; Daniela C Rodríguez; Tomás J Aragón
Journal:  BMC Public Health       Date:  2012-01-25       Impact factor: 3.295

9.  Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets.

Authors:  Erhard van der Vries; Koert J Stittelaar; Geert van Amerongen; Edwin J B Veldhuis Kroeze; Leon de Waal; Pieter L A Fraaij; Roland J Meesters; Theo M Luider; Bart van der Nagel; Birgit Koch; Arnold G Vulto; Martin Schutten; Albert D M E Osterhaus
Journal:  PLoS Pathog       Date:  2013-05-23       Impact factor: 6.823

10.  Risk factors for mortality among 2009 A/H1N1 influenza hospitalizations in Maricopa County, Arizona, April 2009 to March 2010.

Authors:  G Chowell; A Ayala; V Berisha; C Viboud; M Schumacher
Journal:  Comput Math Methods Med       Date:  2012-07-15       Impact factor: 2.238

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.